NZ596490A - Monoclonal antibodies that bind GT468 for the treatment of cancer - Google Patents

Monoclonal antibodies that bind GT468 for the treatment of cancer

Info

Publication number
NZ596490A
NZ596490A NZ596490A NZ59649009A NZ596490A NZ 596490 A NZ596490 A NZ 596490A NZ 596490 A NZ596490 A NZ 596490A NZ 59649009 A NZ59649009 A NZ 59649009A NZ 596490 A NZ596490 A NZ 596490A
Authority
NZ
New Zealand
Prior art keywords
treatment
monoclonal antibodies
bind
cancer
disclosed
Prior art date
Application number
NZ596490A
Other languages
English (en)
Inventor
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Rita Mitnacht-Kraus
Original Assignee
Ganymed Pharmaceuticals Ag
Univ Mainz Johannes Gutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Ag
Publication of NZ596490A publication Critical patent/NZ596490A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ596490A 2008-09-16 2009-09-16 Monoclonal antibodies that bind GT468 for the treatment of cancer NZ596490A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
NZ591004A NZ591004A (en) 2008-09-16 2009-09-16 Monoclonal antibodies that bind GT468 for the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ596490A true NZ596490A (en) 2013-05-31

Family

ID=40589589

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596490A NZ596490A (en) 2008-09-16 2009-09-16 Monoclonal antibodies that bind GT468 for the treatment of cancer
NZ591004A NZ591004A (en) 2008-09-16 2009-09-16 Monoclonal antibodies that bind GT468 for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ591004A NZ591004A (en) 2008-09-16 2009-09-16 Monoclonal antibodies that bind GT468 for the treatment of cancer

Country Status (27)

Country Link
US (1) US8946388B2 (OSRAM)
EP (3) EP2166021A1 (OSRAM)
JP (1) JP2012502938A (OSRAM)
KR (1) KR101818741B1 (OSRAM)
CN (3) CN105753988A (OSRAM)
AU (1) AU2009294896B2 (OSRAM)
BR (1) BRPI0918178B8 (OSRAM)
CA (1) CA2732594C (OSRAM)
CY (1) CY1119956T1 (OSRAM)
DK (1) DK2342234T3 (OSRAM)
ES (1) ES2659718T3 (OSRAM)
HK (1) HK1253579A1 (OSRAM)
HR (1) HRP20180262T1 (OSRAM)
HU (1) HUE036477T2 (OSRAM)
IL (2) IL211010A (OSRAM)
LT (1) LT2342234T (OSRAM)
MX (2) MX357010B (OSRAM)
NO (1) NO2342234T3 (OSRAM)
NZ (2) NZ596490A (OSRAM)
PL (1) PL2342234T3 (OSRAM)
PT (1) PT2342234T (OSRAM)
RS (1) RS56937B1 (OSRAM)
SI (1) SI2342234T1 (OSRAM)
SM (1) SMT201800079T1 (OSRAM)
TR (1) TR201802090T4 (OSRAM)
WO (1) WO2010031551A2 (OSRAM)
ZA (1) ZA201100835B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) * 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
MX354450B (es) * 2011-01-19 2018-03-05 Cantargia Ab Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP4541378A3 (en) 2013-11-14 2025-07-30 Endocyte, Inc. Compounds for positron emission tomography
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3277716B1 (en) * 2015-04-03 2020-06-24 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
AU2016291803A1 (en) * 2015-07-14 2018-02-22 Medlmmune, Llc Compositions and methods for treating cancer
CN108348581B (zh) * 2015-09-04 2022-07-01 斯克利普斯研究所 胰岛素免疫球蛋白融合蛋白
AU2016363770A1 (en) * 2015-12-01 2018-06-28 Genmab B.V. Anti-DR5 antibodies and methods of use thereof
KR20220104298A (ko) 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
JP2020513819A (ja) * 2017-03-15 2020-05-21 スージョウ ギャラクシー バイオファーマ カンパニー リミテッド Ｃｔｌａ４抗体、医薬組成物およびその使用
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EA007958B1 (ru) 2000-08-03 2007-02-27 Терапеутик Хьюман Поликлоналз Инк. ТРАНСГЕННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ГУМАНИЗИРОВАННЫЙ ЛОКУС Ig, И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПОЛУЧЕНИЯ ТРАНСГЕННЫХ ЖИВОТНЫХ
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
ATE533857T1 (de) 2003-01-17 2011-12-15 Univ Hong Kong Chinese Zirkulierende mrna als diagnostische marker für erkankungen die mit einer schwangerschaft zusammenhängen
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CA2750985C (en) 2009-02-20 2022-07-19 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
NO2342234T3 (OSRAM) 2018-04-14
IL242204A0 (en) 2015-11-30
CN102164963A (zh) 2011-08-24
BRPI0918178A2 (pt) 2015-12-01
CN102164963B (zh) 2015-07-29
SMT201800079T1 (it) 2018-03-08
BRPI0918178B1 (pt) 2021-04-06
RS56937B1 (sr) 2018-05-31
MX357010B (es) 2018-06-22
ES2659718T3 (es) 2018-03-19
ZA201100835B (en) 2014-04-30
LT2342234T (lt) 2018-03-12
CN104628858B (zh) 2018-11-16
IL242204B (en) 2020-09-30
EP2166021A1 (en) 2010-03-24
WO2010031551A3 (en) 2010-09-16
EP2342234A2 (en) 2011-07-13
CY1119956T1 (el) 2018-12-12
DK2342234T3 (en) 2018-02-26
JP2012502938A (ja) 2012-02-02
BRPI0918178A8 (pt) 2020-05-19
AU2009294896A1 (en) 2010-03-25
IL211010A (en) 2015-11-30
EP2342234B1 (en) 2017-11-15
CN105753988A (zh) 2016-07-13
CN104628858A (zh) 2015-05-20
US20110223182A1 (en) 2011-09-15
HUE036477T2 (hu) 2018-07-30
BRPI0918178B8 (pt) 2021-05-25
PT2342234T (pt) 2018-02-21
SI2342234T1 (en) 2018-04-30
WO2010031551A2 (en) 2010-03-25
NZ591004A (en) 2012-03-30
MX2011002856A (es) 2011-06-28
KR20110055699A (ko) 2011-05-25
IL211010A0 (en) 2011-04-28
US8946388B2 (en) 2015-02-03
TR201802090T4 (tr) 2018-03-21
CA2732594A1 (en) 2010-03-25
PL2342234T3 (pl) 2018-07-31
HK1253579A1 (en) 2019-06-21
KR101818741B1 (ko) 2018-01-15
HRP20180262T1 (hr) 2018-03-23
EP3312198A1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
UA103004C2 (ru) Гуманизированное антитело против cd79b и иммуноконъюгаты и способы применения
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
MY157403A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
IL184617A0 (en) Dr5 antibodies and uses thereof
MX339621B (es) Anticuerpos que se unen a cd27 humano y uso de los mismos.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA201171374A1 (ru) Антитела против cd100 и способы их применения
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2010001378A (es) Uso terapeutico de anticuerpos del receptor anti-tweak.
MX354143B (es) Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
NZ607588A (en) Antibodies against human TWEAK and uses thereof
MX2018006372A (es) Anticuerpos anti-5t4 y conjugados de anticuerpos-farmacos.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
TN2011000417A1 (en) Humanised antibodies with anti-tumour activity
WO2008118324A3 (en) Composition and method of treating cancer with an anti-uroplakin ib antibody
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
TW200640948A (en) DR5 antibodies and uses thereof
NZ717883A (en) Monoclonal antibodies against her2

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER; FILING DATE: 23 NOV 2011; STATUS: REJECTED; TITLE: MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER; FILING DATE: 17 NOV 2011; STATUS: REJECTED; TITLE: MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER; FILING DATE: 17 DEC 2012; STATUS: REJECTED; TITLE: MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER; FILING DATE: 17 JAN 2013; STATUS: PROPOSED;

Effective date: 20130228

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2016 BY JAMES + WELLS

Effective date: 20130910

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2017 BY JAMES + WELLS

Effective date: 20160906

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2018 BY JAMES + WELLS

Effective date: 20170908

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 SEP 2019 BY PAVIS GMBH

Effective date: 20180911

LAPS Patent lapsed